Neuroscience News and Research

RSS

Comparative study reveals similar brain networks in human and monkey brains

A study published this week in PNAS provides a comprehensive comparative functional anatomy study in human and monkey brains which reveals highly similar brain networks preserved across evolution.

4 Nov 2009

International Omega-3 Awareness Day to educate public about proven health benefits of omega-3

Scientific evidence of the health benefits of omega-3's are now so firmly established that omega-3 expert Carol A. Locke, MD, with a team of world-renowned doctors, has spearheaded the first ever International Omega-3 Awareness Day on March 3rd, 2010. Learn more at www.Omega3Day.com.

4 Nov 2009

Cannabinoids play an important role in stress-related disorders: Study

Use of cannabinoids (marijuana) could assist in the treatment of post-traumatic stress disorder patients. This is exposed in a new study carried out at the Learning and Memory Lab in the University of Haifa's Department of Psychology. The study, carried out by research student Eti Ganon-Elazar under the supervision of Dr. Irit Akirav, was published in the prestigious Journal of Neuroscience.

4 Nov 2009

Inner sense of cardiovascular state relies on two independent pathways, shows study

A new study suggests that the inner sense of our cardiovascular state, our "interoceptive awareness" of the heart pounding, relies on two independent pathways, contrary to what had been asserted by prominent researchers.

4 Nov 2009

Program to address neuroscientific progress in pain management

On November 13, the Center for Neurotechnology Studies at the Potomac Institute for Policy Studies will present the lecture “From a Neuroscience of Pain to a Neuroethics of Care” by Prof. James Giordano, internationally known for his work on the neuroscience and neuroethics of pain.

4 Nov 2009

Study: Estrogen replacement may help protect brain damage

Eighteen years ago this month the National Institutes of Health (NIH) announced that it would sponsor a landmark study to examine women and cardiovascular disease. Known as the Women's Health Initiative (WHI), the study enrolled more than 161,000 women.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

Quintiles to deliver AstraZeneca’s clinical pharmacology studies

Quintiles today announced that it has entered into in an industry-leading clinical pharmacology alliance with AstraZeneca to deliver AstraZeneca’s clinical pharmacology studies across multiple therapy areas and around the globe.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

NuPathe and SurModics sign a drug delivery technology license agreement

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and NuPathe Inc., a neuroscience-focused specialty pharmaceutical company, announced today that the companies have entered into a license agreement for drug delivery technology.

3 Nov 2009

Brain disorder that causes early dementia is highly hereditary: Study

New research shows that a rare brain disorder that causes early dementia is highly hereditary. The study is published in the November 3, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.

3 Nov 2009

Lipid may be vital to learning

Saturated fats have a deservedly bad reputation, but Johns Hopkins scientists have discovered that a sticky lipid occurring naturally at high levels in the brain may help us memorize grandma's recipe for cinnamon buns, as well as recall how, decades ago, she served them up steaming from the oven.

31 Oct 2009

Johns Hopkins researchers find life in blood-starved retinas; shed light on vision loss

Like all tissues in the body, the eye needs a healthy blood supply to function properly. Poorly developed blood vessels can lead to visual impairment or even blindness. While many of the molecules involved in guiding the development of the intricate blood vessel architecture are known, only now are we learning how these molecules work and how they might affect sight.

31 Oct 2009

Quintiles and Eisai partner to develop potential oncology products

Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of cancer patients worldwide.

31 Oct 2009

Think First’s recommendation to centralize patient scheduling and registration for ambulatory clinics implemented

Think First announced today that the Hospital of Saint Raphael (HSR) has successfully implemented Think First’s recommendation to centralize patient scheduling and registration for their ambulatory clinics. The Hospital of Saint Raphael has worked closely with Think First consultants to execute this plan and has seen immediate results.

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

New teleneurology medicine program to provide 24-hour emergency services launched

Rural and small, suburban hospitals in North Carolina and Virginia can now provide a higher level of emergency stroke and critical neurology care, 24 hours a day, 365 days a year, as part of a new teleneurology medicine program announced Oct. 26, 2009, by Forsyth Medical Center (FMC).

31 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009